| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | Director, Former 10% Owner
6 companies
Nashat Amir is a Director, 10% Owner at Syros Pharmaceuticals, Inc. with holdings across 6 companies. Recent SEC Form 4 filings include 6 buys and 16 sells.
Estimated insider holdings value: $1.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2017 | RNAC Cartesian Therapeutics, Inc. | Director | Sell | 79,211 | $19.13 | $1,515,663.89 | -2.3% | |
| Sep 21, 2017 | RNAC Cartesian Therapeutics, Inc. | Director | Sell | 147,187 | $19.91 | $2,930,214.88 | -3.9% | |
| Jul 6, 2016 | SYRS Syros Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +33.7% | |
| Jun 27, 2016 | RNAC Cartesian Therapeutics, Inc. | Director, 10% Owner | Buy | 150,000 | $14.00 | $2,100,000.00 | +8.6% |